Vioxx debacle: A class effect?

NEJM with two early release articles. One by cardiologist Eric Topol, and the other questioning whether Celebrex and other COX-2’s have similar cardiovascular risk.

Related posts:

1. Topol on Russert
2. The left-leaning NEJM
3. COURAGE trial: The NEJM strikes back
4. Primary care: "Second class citizens"
5. Does aspirin prevent fatal heart attack and stroke?
6. Pharmacogenomics: "Physicians are the sitting ducks in this new class of litigation"
7. Stents and the COURAGE trial

  Follow on Twitter   Subscribe